Daniel Todt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4102138/publications.pdf

Version: 2024-02-01

116	6,252	31 h-index	74
papers	citations		g-index
133	133 docs citations	133	10059
all docs		times ranked	citing authors

#	Article	IF	CITATIONS
1	Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C. Journal of Infectious Diseases, 2022, 226, 441-452.	4.0	18
2	Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2. Journal of Hospital Infection, 2022, 120, 9-13.	2.9	12
3	Imprint of unconventional Tâ€eell response in acute hepatitis C persists despite successful early antiviral treatment. European Journal of Immunology, 2022, 52, 472-483.	2.9	8
4	Hepatitis E virus is highly resistant to alcohol-based disinfectants. Journal of Hepatology, 2022, 76, 1062-1069.	3.7	11
5	Evaluation of the substitution of poliomyelitis virus for testing virucidal activities of instrument and surface disinfection. Journal of Hospital Infection, 2022, 122, 60-63.	2.9	1
6	Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance. Virus Evolution, 2022, 8, veac007.	4.9	10
7	Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment. Zeitschrift Fur Gastroenterologie, 2022, 60, .	0.5	O
8	Differential interferon- \hat{l}_{\pm} subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	33
9	Risk Stratification of SARS-CoV-2 Breakthrough Infections Based on an Outbreak at a Student Festive Event. Vaccines, 2022, 10, 432.	4.4	O
10	Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems. Cells, 2022, 11, 927.	4.1	6
11	A touch transfer assay to determine surface transmission of highly pathogenic viruses. STAR Protocols, 2022, 3, 101188.	1.2	O
12	Risk assessment of banknotes as a fomite of SARSâ€CoVâ€2 in cash payment transactions. Risk Analysis, 2022, , .	2.7	4
13	Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 Patients. Journal of Infectious Diseases, 2022, 226, 1608-1615.	4.0	12
14	Experimental cross-species infection of donkeys with equine hepacivirus and analysis of host immune signatures. One Health Outlook, 2022, 4, 9.	3.4	1
15	Mouthrinses against SARS-CoV-2 – High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial. Virus Research, 2022, 316, 198791.	2,2	18
16	Identification of structurally re-engineered rocaglates as inhibitors against hepatitis E virus replication. Antiviral Research, 2022, 204, 105359.	4.1	4
17	An Equine Model for Vaccination against a Hepacivirus: Insights into Host Responses to E2 Recombinant Protein Vaccination and Subsequent Equine Hepacivirus Inoculation. Viruses, 2022, 14, 1401.	3.3	O
18	Pasteurization Inactivates SARS-CoV-2–Spiked Breast Milk. Pediatrics, 2021, 147, .	2.1	18

#	Article	IF	Citations
19	Virus–Host Cell Interplay during Hepatitis E Virus Infection. Trends in Microbiology, 2021, 29, 309-319.	7.7	42
20	Persistence of Pathogens on Inanimate Surfaces: A Narrative Review. Microorganisms, 2021, 9, 343.	3.6	77
21	Initial Hepatitis C Virus Infection of Adult Hepatocytes Triggers a Temporally Structured Transcriptional Program Containing Diverse Pro- and Antiviral Elements. Journal of Virology, 2021, 95,	3.4	13
22	Significant compartmentâ€specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. Liver International, 2021, 41, 1815-1823.	3.9	4
23	Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease. Viruses, 2021, 13, 609.	3.3	129
24	Hepatitis E: An update on One Health and clinical medicine. Liver International, 2021, 41, 1462-1473.	3.9	63
25	Comparison of the in-vitro efficacy of different mouthwash solutions targeting SARS-CoV-2 based on the European Standard EN 14476. Journal of Hospital Infection, 2021, 111, 180-183.	2.9	31
26	The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection. Liver International, 2021, 41, 2046-2058.	3.9	3
27	Comparable Environmental Stability and Disinfection Profiles of the Currently Circulating SARS-CoV-2 Variants of Concern B.1.1.7 and B.1.351. Journal of Infectious Diseases, 2021, 224, 420-424.	4.0	35
28	Virucidal efficacy of different formulations for hand and surface disinfection targeting SARS CoV-2. Journal of Hospital Infection, 2021, 112, 27-30.	2.9	13
29	Antiviral Effect of Budesonide against SARS-CoV-2. Viruses, 2021, 13, 1411.	3.3	13
30	Hepatitis E virus persists in the ejaculate of chronically infected men. Journal of Hepatology, 2021, 75, 55-63.	3.7	17
31	Clinical Course of Infection and Cross-Species Detection of Equine Parvovirus-Hepatitis. Viruses, 2021, 13, 1454.	3.3	8
32	A realistic transfer method reveals low risk of SARS-CoV-2 transmission via contaminated euro coins and banknotes. IScience, 2021, 24, 102908.	4.1	21
33	Students in Dormitories Were Not Major Drivers of the Pandemic during Winter Term 2020/2021: A Cohort Study with RT-PCR and Antibody Surveillance in a German University City. Covid, 2021, 1, 345-356.	1.5	0
34	SARS-CoV-2 N gene dropout and N gene Ct value shift as indicator for the presence of B.1.1.7 lineage in a commercial multiplex PCR assay. Clinical Microbiology and Infection, 2021, 27, 1353.e1-1353.e5.	6.0	39
35	Virucidal efficacy of an ozone-generating system for automated room disinfection. Journal of Hospital Infection, 2021, 116, 16-20.	2.9	5
36	The C-Mannosylome of Human Induced Pluripotent Stem Cells Implies a Role for ADAMTS16 C-Mannosylation in Eye Development. Molecular and Cellular Proteomics, 2021, 20, 100092.	3.8	7

#	Article	IF	Citations
37	Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies. Gut, 2021, 70, 1734-1745.	12.1	15
38	Reply to Lamarca et al. Journal of Infectious Diseases, 2021, 223, 1114-1115.	4.0	0
39	Beyond the Usual Suspects: Hepatitis E Virus and Its Implications in Hepatocellular Carcinoma. Cancers, 2021, 13, 5867.	3.7	15
40	A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets. PLoS Biology, 2021, 19, e3001490.	5.6	33
41	Robust hepatitis E virus infection and transcriptional response in human hepatocytes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1731-1741.	7.1	67
42	Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines, 2020, 8, 386.	4.4	75
43	Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2. Journal of Infectious Diseases, 2020, 222, 1289-1292.	4.0	146
44	Absence of cGAS-mediated type I IFN responses in HIV-1â€"infected T cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 19475-19486.	7.1	20
45	LY6E impairs coronavirus fusion and confers immune control of viral disease. Nature Microbiology, 2020, 5, 1330-1339.	13.3	170
46	Hepatitis E Virus Infection: Circulation, Molecular Epidemiology, and Impact on Global Health. Pathogens, 2020, 9, 856.	2.8	63
47	Significant compartment-specific impact of the RNA extraction and quantification method on the sensitivity of hepatitis E virus detection: implications for clinical care?. Journal of Hepatology, 2020, 73, S852.	3.7	0
48	Clinical and molecular characterization of the human kidney as extrahepatic site of hepatitis E virus infection. Journal of Hepatology, 2020, 73, S833-S834.	3.7	0
49	Liver-expressed <i>Cd302</i> and <i>Cr11</i> limit hepatitis C virus cross-species transmission to mice. Science Advances, 2020, 6, .	10.3	23
50	Hepatitis E virus is effectively inactivated in platelet concentrates by ultraviolet C light. Vox Sanguinis, 2020, 115, 555-561.	1.5	5
51	Temperature-dependent surface stability of SARS-CoV-2. Journal of Infection, 2020, 81, 452-482.	3.3	89
52	Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 by WHO-Recommended Hand Rub Formulations and Alcohols. Emerging Infectious Diseases, 2020, 26, 1592-1595.	4.3	299
53	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E – The HepNet SofE pilot study. Journal of Hepatology, 2020, 73, 696-699.	3.7	39
54	Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. Journal of Hospital Infection, 2020, 104, 246-251.	2.9	2,758

#	Article	IF	CITATIONS
55	C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle. Journal of Hepatology, 2020, 73, 549-558.	3.7	35
56	A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks. Journal of Visualized Experiments, 2020, , .	0.3	4
57	Virucidal efficacy of glutaraldehyde for instrument disinfection. GMS Hygiene and Infection Control, 2020, 15, Doc34.	0.3	2
58	In-vitro activity of active ingredients of disinfectants against drug-resistant fungi. Journal of Hospital Infection, 2019, 103, 468-473.	2.9	5
59	Evaluation of the virucidal efficacy of disinfectant wipes with a test method simulating practical conditions. Antimicrobial Resistance and Infection Control, 2019, 8, 121.	4.1	29
60	Chronic equine hepacivirus infection in an adult gelding with severe hepatopathy. Veterinary Medicine and Science, 2019, 5, 372-378.	1.6	18
61	SAT-204-Hepatitis E virus antigen in urine as a useful diagnostic Background and aims: for monitoring infection and detection of recent infection. Journal of Hepatology, 2019, 70, e719.	3.7	0
62	Characterization of Equine Parvovirus in Thoroughbred Breeding Horses from Germany. Viruses, 2019, 11, 965.	3.3	24
63	Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment. Pathogens, 2019, 8, 129.	2.8	5
64	High tolerance of hepatitis B virus to thermal disinfection. Journal of Hepatology, 2019, 71, 1249-1251.	3.7	5
65	Equine Parvovirus-Hepatitis Frequently Detectable in Commercial Equine Serum Pools. Viruses, 2019, 11, 461.	3.3	20
66	Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. Journal of Hepatology, 2019, 71, 673-684.	3.7	25
67	Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver. Cells, 2019, 8, 610.	4.1	5
68	Hepatitis E Virus Drug Development. Viruses, 2019, 11, 485.	3.3	37
69	FRI-133-HCV neutralizing antibody responses in natural infections mapped by metric multi-dimensional scaling reveals new insights into HCV antigenicity and broadly neutralzing antibodies. Journal of Hepatology, 2019, 70, e446.	3.7	0
70	A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. Journal of Hepatology, 2019, 70, 1082-1092.	3.7	15
71	Influence of Tattoo Ink on Hepatitis C Virus Infectiousness. Open Forum Infectious Diseases, 2019, 6, ofz047.	0.9	1
72	Characterization of Endogenous SERINC5 Protein as Anti-HIV-1 Factor. Journal of Virology, 2019, 93, .	3.4	17

#	Article	IF	Citations
73	Clinical Outcome and Viral Genome Variability of Hepatitis B Virus–Induced Acute Liver Failure. Hepatology, 2019, 69, 993-1003.	7.3	19
74	Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. Journal of Hepatology, 2019, 70, 593-602.	3.7	20
75	SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. Journal of Hepatology, 2019, 70, 603-614.	3.7	9
76	Cell culture systems for the study of hepatitis E virus. Antiviral Research, 2019, 163, 34-49.	4.1	60
77	High Environmental Stability of Hepatitis B Virus and Inactivation Requirements for Chemical Biocides. Journal of Infectious Diseases, 2019, 219, 1044-1048.	4.0	13
78	Hepatitis E virus replication and interferon responses in human placental cells. Hepatology Communications, 2018, 2, 173-187.	4.3	40
79	Hepatitis E virus replication and interferonresponse in human placental-derived cells. Journal of Hepatology, 2018, 68, S786.	3.7	0
80	Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse. Current Opinion in Virology, 2018, 32, 80-87.	5.4	49
81	The Small-Compound Inhibitor K22 Displays Broad Antiviral Activity against Different Members of the Family Flaviviridae and Offers Potential as a Panviral Inhibitor. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9
82	Interferon-beta expression and type I interferon receptor signaling of hepatocytes prevent hepatic necrosis and virus dissemination in Coxsackievirus B3-infected mice. PLoS Pathogens, 2018, 14, e1007235.	4.7	22
83	The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo. Antiviral Research, 2018, 157, 151-158.	4.1	62
84	Environmental Stability and Infectivity of Hepatitis C Virus (HCV) in Different Human Body Fluids. Frontiers in Microbiology, 2018, 9, 504.	3 . 5	7
85	Mutations in HCV NS3 but no Sec14L2 variants alter HCV RNA replication of natural occuring viruses in cell culture. Journal of Hepatology, 2018, 68, S763-S764.	3.7	0
86	First detection and frequent occurrence of Equine Hepacivirus in horses on the African continent. Veterinary Microbiology, 2018, 223, 51-58.	1.9	13
87	Exophiala dermatitidis isolates from various sources: using alternative invertebrate host organisms (Caenorhabditis elegans and Galleria mellonella) to determine virulence. Scientific Reports, 2018, 8, 12747.	3.3	9
88	Susceptibility of Chikungunya Virus to Inactivation by Heat and Commercially and World Health Organization-Recommended Biocides. Journal of Infectious Diseases, 2018, 218, 1507-1510.	4.0	2
89	Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy. Antiviral Research, 2017, 139, 129-137.	4.1	5
90	Exacerbation d'infection par le virus de l'hépatite E au cours d'un traitement par anti-TNFα. Revue Rhumatisme (Edition Francaise), 2017, 84, 244-247.	Du _{o.o}	0

#	Article	IF	Citations
91	Immune protection against reinfection with nonprimate hepacivirus. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2430-E2439.	7.1	42
92	Virucidal Activity of World Health Organization–Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses. Journal of Infectious Diseases, 2017, 215, 902-906.	4.0	151
93	Hepatitis C Virus Strain-Dependent Usage of Apolipoprotein E Modulates Assembly Efficiency and Specific Infectivity of Secreted Virions. Journal of Virology, 2017, 91, .	3.4	21
94	Exacerbation of hepatitis E virus infection during anti-TNFα treatment. Joint Bone Spine, 2017, 84, 217-219.	1.6	9
95	Differential Infection Patterns and Recent Evolutionary Origins of Equine Hepaciviruses in Donkeys. Journal of Virology, 2017, 91, .	3.4	45
96	Virucidal efficacy of peracetic acid for instrument disinfection. Antimicrobial Resistance and Infection Control, 2017, 6, 114 .	4.1	17
97	Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw572.	3.0	1
98	Mutagenic Effects of Ribavirin on Hepatitis E Virusâ€"Viral Extinction versus Selection of Fitness-Enhancing Mutations. Viruses, 2016, 8, 283.	3.3	43
99	Extraâ€hepatic replication and infection of hepatitis E virus in neuronalâ€derived cells. Journal of Viral Hepatitis, 2016, 23, 512-521.	2.0	104
100	Acute and chronic infections with nonprimate hepacivirus in young horses. Veterinary Research, 2016, 47, 97.	3.0	20
101	Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection. Journal of Infectious Diseases, 2016, 214, 361-368.	4.0	52
102	In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut, 2016, 65, 1733-1743.	12.1	145
103	Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission. Journal of Virology, 2016, 90, 10670-10681.	3.4	27
104	Apolipoprotein E polymorphisms and their protective effect on hepatitis E virus replication. Hepatology, 2016, 64, 2274-2276.	7.3	7
105	Inactivation of HCV and HIV by microwave: a novel approach for prevention of virus transmission among people who inject drugs. Scientific Reports, 2016, 6, 36619.	3.3	14
106	Emergence of linezolid- and vancomycin-resistant Enterococcus faecium in a department for hematologic stem cell transplantation. Antimicrobial Resistance and Infection Control, 2016, 5, 31.	4.1	29
107	Development and virucidal activity of a novel alcohol-based hand disinfectant supplemented with urea and citric acid. BMC Infectious Diseases, 2016, 16, 77.	2.9	50
108	Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrobial Agents and Chemotherapy, 2016, 60, 2132-2139.	3.2	75

#	Article	lF	CITATIONS
109	Vertical transmission of hepatitis C virus-like non-primate hepacivirus in horses. Journal of General Virology, 2016, 97, 2540-2551.	2.9	25
110	Interferonâ€inducible cholesterolâ€25â€hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation. Hepatology, 2015, 62, 702-714.	7.3	78
111	Mechanisms of Methods for Hepatitis C Virus Inactivation. Applied and Environmental Microbiology, 2015, 81, 1616-1621.	3.1	46
112	Assessment of cross-species transmission of hepatitis C virus-related non-primate hepacivirus in a population of humans at high risk of exposure. Journal of General Virology, 2015, 96, 2636-2642.	2.9	19
113	Several Human Liver Cell Expressed Apolipoproteins Complement HCV Virus Production with Varying Efficacy Conferring Differential Specific Infectivity to Released Viruses. PLoS ONE, 2015, 10, e0134529.	2.5	30
114	Incidence Rate of SARS-CoV-2 Infection Among Students Living in Dormitories - A Prospective Cohort Study With RT-PCR and SARS-CoV-2 Antibody Surveillance in a German University City. SSRN Electronic Journal, 0, , .	0.4	0
115	Holder Pasteurization Inactivates SARS-CoV-2 in Human Breast Milk. SSRN Electronic Journal, 0, , .	0.4	0
116	Catch Me (If You Can): Assessing the Risk of SARS-CoV-2 Transmission Via Euro Cash. SSRN Electronic Journal, 0, , .	0.4	5